Drugs Made in America Acquisition II receives $250,000 in convertible note financing from Tal Alpha
DMII•Drugs Made in America Acquisition II received $250,000 from Tal Alpha on November 6, bringing funding under a $1.4 million convertible note financing to $700,000, with another $700,000 available.
1. Convertible note financing
Drugs Made in America Acquisition II received $250,000 from Tal Alpha Yezum Vekidum Asakim (2003) on November 6, 2026. Total funding under the $1.4 million financing reached $700,000, leaving $700,000 available. Existing borrowings will be consolidated into a $700,000 convertible promissory note maturing June 30, 2027, extending prior notes’ December 2026 maturities.
2. Conversion terms
After a business combination, the investor may convert the note into shares of the combined entity at a 35% discount to market price. The funding commitment is not contingent on approval or closing of the proposed business combination with Alpha AI Biotech Group.




